The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Flagged first, then by citations
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 201–300 of 849
Miroddi, M., Sterrantino, C., Simmonds, M. C., Caridi, L., Calapai, G., Phillips, R. S., & Stewart, L. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30280 · Cited by 52
Antiangiogenic therapy: Markers of response, “normalization” and resistance
Alaoui‐Lasmaili, K. E., & Faivre‐Fiorina, B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.001 · Cited by 52
Li, Y., Du, Y., Xue, C., Wu, P., Du, N., Zhu, G., Xu, H., & Zhi, Z. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02511-7 · Cited by 52
Sidhu, R., Rong, A., & Dahlberg, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2502 · Cited by 53
Artificial Intelligence for Precision Oncology
Bhalla, S., & Laganà, A. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-91836-1_14 · Cited by 52
Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., & Barni, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0650-4 · Cited by 50
Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
da Costa, A. G., Tejpar, S., Prenen, H., & Cutsem, E. V. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0200-y · Cited by 49
Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases
Feng, Q. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4263 · Cited by 49
Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
Kudo, M. (2011) · Digestive Diseases · doi:10.1159/000327562 · Cited by 50
Reddy, S. M., Kopetz, S., Morris, J. S., Parikh, N. U., Qiao, W., Overman, M. J., Fogelman, D. R., Shureiqi, I., Jacob, C., Malik, Z., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0257-z · Cited by 55
Galfrascoli, E., Piva, S., Cinquini, M., Rossi, A., Verde, N. M. L., Bramati, A., Moretti, A., Manazza, A. D., Damia, G. L. M., Torri, V., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.010 · Cited by 48
ERBB oncogene proteins as targets for monoclonal antibodies
Polanovsky, O. L., Lebedenko, E. N., & Deyev, S. M. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912030029 · Cited by 49
Kobunai, T., Watanabe, T., Yamamoto, Y., & Eshima, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.167 · Cited by 49
Siena, S., Glynne‐Jones, R., Adenis, A., Thaler, J., Preusser, P., Aguilar, E. A., Aapro, M., Loos, A. H., Esser, R., & Wilke, H. (2010) · Cancer · doi:10.1002/cncr.24945 · Cited by 50
Kudo, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i42.6005 · Cited by 49
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Luo, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3858 · Cited by 51
Meyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A.-W., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 48
Banck, M. S., & Grothey, A. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0188 · Cited by 47
Abdel-Rahman, O. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.09.008 · Cited by 48
Guedes, J. G., Veiga, I., Rocha, P., Pinto, P., Pinto, C., Pinheiro, M., Peixoto, A., Fragoso, M., Raimundo, A. C., Ferreira, P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-169 · Cited by 48
Therapeutic modulation of k-ras signaling in colorectal cancer
Krens, L. L., Baas, J. M., Gelderblom, H. A. J., & Guchelaar, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.012 · Cited by 46
Chua, W. M., Kho, P. S., Moore, M. M., Charles, K. A., & Clarke, S. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.012 · Cited by 45
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 50
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection
Power, D. G., & Kemeny, N. E. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.08.001 · Cited by 45
Glockzin, G., Rochon, J., Arnold, D., Lang, S. A., Klebl, F. H., Zeman, F., Koller, M. T., Schlitt, H. J., & Piso, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-67 · Cited by 45
Eng, C. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0167 · Cited by 45
Aflibercept in the Treatment of Metastatic Colorectal Cancer
Wang, T.-F., & Lockhart, A. C. (2012) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s7432 · Cited by 44
Therapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_6 · Cited by 44
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43
Hofheinz, R., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.032 · Cited by 44
Molecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
Current and advancing treatments for metastatic colorectal cancer
Sanz‐García, E., Grasselli, J., Argilés, G., Elez, M. E., & Tabernero, J. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1108405 · Cited by 42
Dotan, E., Meropol, N. J., Zhu, F., Zambito, F., Bove, B. A., Cai, K. Q., Godwin, A. K., Golemis, E. A., Astsaturov, I. A., & Cohen, S. J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.587 · Cited by 40
Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies
Nedergaard, M. K., Hedegaard, C. J., & Poulsen, H. S. (2012) · BioDrugs · doi:10.2165/11599760-000000000-00000 · Cited by 40
Lin, A. Y., Buckley, N. S., Lu, A.-T. T., Kouzminova, N. B., & Salpeter, S. R. (2011) · Clinical Colorectal Cancer · doi:10.3816/ccc.2011.n.009 · Cited by 45
Díaz‐Rubio, E., Gómez‐España, A., Massutí, B., Sastre, J., Reboredo, M., Manzano, J. L., Rivera, F., Safont7, M., Montagut, C. O., González‐Flores, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047345 · Cited by 41
Combination Radioimmunotherapy Strategies for Solid Tumors
Zaheer, J., Kim, H., Lee, Y., Kim, J. S., & Lim, S. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225579 · Cited by 41
Evolution of systemic therapy for advanced pancreatic cancer
Renouf, D. J., & Moore, M. J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.21 · Cited by 41
EGFR Antibodies in Colorectal Cancer: Where Do They Belong?
Grothey, A. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3407 · Cited by 41
Sastre, J., Vidaurreta, M., Gómez, A., Rivera, F., Massutí, B., López, M. R., Abad, A., Gallén, M., Benavides, M., Aranda, E., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.06.001 · Cited by 40
Role of Biologics in First-Line Treatment of Colorectal Cancer
Mahipal, A., & Grothey, A. F. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 42
Kelley, R. K., Bebber, S. L. V., Phillips, K. A., & Venook, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0004 · Cited by 40
Li, L., Dong, H., Zhao, F., Tang, J., Chen, X., Ding, J., Men, H.-T., Luo, W.-X., Du, Y., Ge, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.013 · Cited by 39
Gouverneur, A., Salvo, F., Berdaï, D., Moore, N. D., Fourrier‐Réglat, A., & Noïze, P. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.08.001 · Cited by 41
Abdel-Rahman, O. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.10.006 · Cited by 39
Abdel-Rahman, O. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.12.006 · Cited by 38
Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer
Mao, C., Zeng, X., Zhang, C., Yang, Y., Xiao, X., Luan, S., Zhang, Y., & Yuan, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.612451 · Cited by 38
Loupakis, F., Cremolini, C., Salvatore, L., Schirripa, M., Lonardi, S., Vaccaro, V., Cuppone, F., Giannarelli, D., Zagonel, V., Cognetti, F., et al. (2011) · Cancer · doi:10.1002/cncr.26460 · Cited by 38
Eribulin: Rediscovering Tubulin as an Anticancer Target
Jimeno, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1023 · Cited by 37
The next steps in next-gen sequencing of cancer genomes
Hayes, D. N., & Kim, W. Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci68339 · Cited by 40
Hepatic metastasis from colorectal cancer
Aloia, T. A., & Vauthey, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00092-3 · Cited by 38
Krause, M., Gurtner, K., Deuse, Y., & Baumann, M. A. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903232835 · Cited by 38
Shen, Z., Wang, B., Luo, J., Jiang, K., Zhang, H., Mustonen, H. K., Puolakkainen, P. A., Zhu, J., Ye, Y., & Wang, S. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.05.002 · Cited by 38
Emerging therapies: angiogenesis inhibitors for ovarian cancer
Jackson, A. L., Eisenhauer, E. L., & Herzog, T. J. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1036739 · Cited by 37
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Dérangère, V., Fumet, J.-D., Boidot, R., Bengrine-Lefèvre, L., Limagne, E., Chevriaux, A., Vincent, J., Ladoire, S., Apétoh, L., Rébé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7008 · Cited by 38
Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling
Zhang, C., Aldrees, M., Arif, M., Li, X., Mardinoğlu, A., & Aziz, M. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00681 · Cited by 39
Kasi, P. M., & Grothey, A. F. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000195 · Cited by 37
Current opinion on optimal treatment for colorectal cancer
Price, T. J., Segelov, E., Burge, M., Haller, D. G., Ackland, S. P., Tebbutt, N. C., Karapetis, C. S., Pavlakis, N., Sobrero, A. F., Cunningham, D., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.37 · Cited by 36
Cetuximab in metastatic colorectal cancer
Broadbridge, V. T., Karapetis, C. S., & Price, T. J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.25 · Cited by 36
Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years
Mayer, R. J., Venook, A. P., & Schilsky, R. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4121 · Cited by 37
Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway
Li, M., Yu, X., Li, W., Liu, T., Deng, G., Liu, W., Liu, H., & Gao, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22077 · Cited by 36
Ather, F., Hamidi, H., Fejzo, M. S., Letrent, S. P., Finn, R. S., Kabbinavar, F. F., Head, C. S., & Wong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056112 · Cited by 36
Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 36
Rose, J. S., Serna, D. S., Martin, L. K., Li, X., Weatherby, L. M., Abdel‐Misih, S., Zhao, W., & Bekaii‐Saab, T. (2012) · Cancer · doi:10.1002/cncr.27666 · Cited by 52
Personalized Colon Cancer Care in 2010
Catenacci, D. V. T., Kozloff, M. F., Kindler, H. L., & Polite, B. N. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.001 · Cited by 35
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Saridaki, Z. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i10.1177 · Cited by 34
Integration of panitumumab into the treatment of colorectal cancer
Grávalos, C., Cassinello, J., Alfonso, P. G., & Jimeno, A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.06.005 · Cited by 35
Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal?
Okines, A. F. C., & Cunningham, D. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.028 · Cited by 35
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 36
Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
Marques, I. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i44.7955 · Cited by 34
Rational engineering of antibody therapeutics targeting multiple oncogene pathways
Fitzgerald, J. B., & Lugovskoy, A. A. (2011) · mAbs · doi:10.4161/mabs.3.3.15299 · Cited by 34
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
Moorcraft, S. Y., Smyth, E. C., & Cunningham, D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13491797 · Cited by 35
Targeted therapy for biliary tract cancers
Faris, J. E., & Zhu, A. X. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-011-0496-0 · Cited by 34
Cetuximab in non-small-cell lung cancer
Carillio, G., Montanino, A., Costanzo, R., Sandomenico, C., Piccirillo, M. C., Maïo, M. D., Daniele, G., Giordano, P., Bryce, J., Normanno, N., et al. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.178 · Cited by 34
Gulhati, P., Yin, J., Pederson, L., Schmoll, H., Hoff, P. M., Douillard, J., Hecht, J. R., Tournigand, C., Tebbut, N. C., Chibaudel, B., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa020 · Cited by 34
Self-citationHurwitz, H. I., Bekaii‐Saab, T., Bendell, J. C., Cohn, A. L., Kozloff, M. F., Roach, N., Mun, Y., Fish, S. M., Flick, E. D., & Grothey, A. A. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.001 · Cited by 35
Self-citationA dual‐targeting antibody against EGFR‐VEGF for lung and head and neck cancer treatment
Zhang, H., Yun, S., Batuwangala, T. D., Steward, M., Holmes, S. D., Pan, L., Tighiouart, M., Shin, H. J. C., Koenig, L., Park, W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26427 · Cited by 34
Impact of KRAS Mutations on Management of Colorectal Carcinoma
Sullivan, K. M., & Kozuch, P. S. (2011) · Pathology Research International · doi:10.4061/2011/219309 · Cited by 36
Past, Present and Future of Targeted Therapy in Solid Tumors
Palazzo, A., Iacovelli, R., & Cortesi, E. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517145 · Cited by 33
Miroddi, M., Sterrantino, C., Simonelli, I., Ciminata, G., Phillips, R. S., & Calapai, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.06.004 · Cited by 33
Do, K. T., Cao, L., Kang, Z., Türkbey, B., Lindenberg, M. L., Larkins, E. A., Holkova, B., Steinberg, S. M., Raffeld, M. A., Peer, C. J., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.02.007 · Cited by 33
Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
Hocking, C. M., & Price, T. J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13498660 · Cited by 33
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 33
Koukourakis, M. I., Giatromanolaki, A. N., Tsoutsou, P. P., Lyratzopoulos, N., Pitiakoudis, M., Kouklakis, G., Chloropoulou, P., Manolas, K., & Sivridis, E. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.02.037 · Cited by 32
Boere, I. A., Hamberg, P., & Sleijfer, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01369.x · Cited by 34
Heindryckx, F., Coulon, S., Terrie, E., Casteleyn, C. R., Stassen, J., Geerts, A. M., Libbrecht, L. J., Allemeersch, J., Carmeliet, P., Colle, I. O., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.032 · Cited by 32
The role of targeted agents in preoperative chemoradiation for rectal cancer
Wadlow, R. C., & Ryan, D. P. (2010) · Cancer · doi:10.1002/cncr.25155 · Cited by 32
Xu, J., Qin, X., Wang, J., Zhang, S., Zhong, Y., Ren, L., Wei, Y., Zeng, S., Wan, D., & Zheng, S. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-0999-8 · Cited by 32
Antiangiogenesis agents in colorectal cancer
Hubbard, J. M., & Grothey, A. F. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328339524e · Cited by 32
Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice
Kudo, M. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0089-y · Cited by 32
Kim, E. S., Moon, J., Herbst, R. S., Redman, M. W., Dakhil, S. R., Velasco, M. R., Hirsch, F. R., Mack, P. C., Kelly, K. L., Heymach, J. V., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000009 · Cited by 32
Advancing bioinformatics with language models: components, applications, and perspectives
Liu, J., Yang, M., Yu, Y., Xu, H., Wang, T., Li, K., & Zhou, X. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag367 · Cited by 66
K- RAS Mutation in the Screening, Prognosis and Treatment of Cancer
Parsons, B. L., & Meng, F. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.95 · Cited by 33
Advances and new perspectives in the treatment of metastatic colon cancer
Recondo, G. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i7.211 · Cited by 31
Zhou, S., Huang, Y., Wei, Y., Jiang, Z.-M., Zhang, Y.-D., Yang, Q., & Xie, D.-R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050925 · Cited by 31
How to select the optimal treatment for first line metastatic colorectal cancer
Stein, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.899 · Cited by 33
Liver Resection for Colorectal Metastases in Older Adults: A Paired Matched Analysis
Benedetto, F. D., Berretta, M., D'Amico, G., Montalti, R., Ruvo, N. D., Cautero, N., Guerrini, G. P., Ballarin, R., Spaggiari, M., Tarantino, G., et al. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03734.x · Cited by 31
Funakoshi, T., Suzuki, M., & Tamura, K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.09.002 · Cited by 30
Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Khan, K. H., Cunningham, D., & Chau, I. (2016) · Current Drug Targets · doi:10.2174/1389450116666150325231555 · Cited by 30
Subbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90380 · Cited by 30
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
